Authors
Mercè Brunet, Teun Van Gelder, Anders Åsberg, Vincent Haufroid, Dennis A Hesselink, Loralie Langman, Florian Lemaitre, Pierre Marquet, Christoph Seger, Maria Shipkova, Alexander Vinks, Pierre Wallemacq, Eberhard Wieland, Jean Baptiste Woillard, Markus J Barten, Klemens Budde, Helena Colom, Maja-Theresa Dieterlen, Laure Elens, Kamisha L Johnson-Davis, Paweł K Kunicki, Iain MacPhee, Satohiro Masuda, Binu S Mathew, Olga Millán, Tomoyuki Mizuno, Dirk-Jan AR Moes, Caroline Monchaud, Ofelia Noceti, Tomasz Pawinski, Nicolas Picard, Ron Van Schaik, Claudia Sommerer, Nils Tore Vethe, Brenda De Winter, Uwe Christians, Stein Bergan
Publication date
2019/6/1
Source
Therapeutic drug monitoring
Volume
41
Issue
3
Pages
261-307
Publisher
LWW
Description
Ten years ago, a consensus report on the optimization of tacrolimus was published in this journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicity (IATDMCT) decided to issue an updated consensus report considering the most relevant advances in tacrolimus pharmacokinetics (PK), pharmacogenetics (PG), pharmacodynamics, and immunologic biomarkers, with the aim to provide analytical and drug-exposure recommendations to assist TDM professionals and clinicians to individualize tacrolimus TDM and treatment. The consensus is based on in-depth literature searches regarding each topic that is addressed in this document. Thirty-seven international experts in the field of TDM of tacrolimus as well as its PG and biomarkers contributed to the drafting of sections most relevant for their expertise. Whenever applicable …
Scholar articles
M Brunet, T Van Gelder, A Åsberg, V Haufroid… - Therapeutic drug monitoring, 2019